HONG KONG, March 30, 2026 /PRNewswire/ — On 30 March, Fosun International (00656.HK) announced its results for the 12 months ended 31 December 2025. In 2025, Fosun’s fundamentals remained solid, core industries such as pharmaceuticals and healthcare and insurance and finance demonstrated a good development trend, and the twin drivers of innovation and globalization delivered strong momentum.
During the Reporting Period, the Group’s total revenue reached RMB173.43 billion, and adjusted industrial operation profit amounted to RMB4 billion. The four core subsidiaries generated RMB128.2 billion in revenue, accounting for 74% of the Group’s total revenue. Among them, Fosun Pharma, a core subsidiary in the Health segment, achieved a net profit attributable to shareholders of the parent of RMB3.371 billion, representing a year-on-year increase of 21.69%; Fosun Insurance Portugal, a core subsidiary in the Wealth segment, reported a net profit attributable to owners of the parent of EUR201 million, up 15.8% year on year.
During the Reporting Period, the Group’s investment in technology innovation reached RMB7.8 billion, and 16 indications of 7 innovative drugs were approved for marketing in China and overseas markets. In addition, nearly 40 innovative drug clinical trials were approved by regulatory authorities in China, the United States and Europe, while multiple core products entered key clinical phases, laying a solid pipeline foundation for subsequent commercial growth.
During the Reporting Period, the Group’s overseas revenue reached RMB94.86 billion, accounting for 54.7% of total revenue, representing a year-on-year increase of 5.4 percentage points. For innovative drugs, …